Engineering chimeric antigen receptor T cells for solid tumour therapy.

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Cell-based immunotherapies, like CAR-T cells, have transformed blood cancer treatment.
• Solid tumors present unique challenges including TME, heterogeneity, and T cell exhaustion, limiting CAR-T efficacy.
• The tumor microenvironment (TME) is a complex milieu of cellular and non-cellular components that critically influences CAR-T cell function.

Purpose of the Study:

• To review the multifaceted challenges posed by the tumor microenvironment (TME) for CAR-T cell therapy in solid tumors.
• To highlight the critical need for understanding CAR-T cell and TME interactions.
• To explore engineering strategies for overcoming TME-associated barriers.

Main Methods:

• Review of current literature on CAR-T cell therapy and solid tumor microenvironments.
• Analysis of TME components including extracellular matrix (ECM), vasculature, and immune suppressive factors.
• Summary of existing and emerging CAR-T cell engineering strategies.

Main Results:

• Identified key TME-associated challenges: T cell trafficking, ECM barriers, abnormal vasculature, tumor heterogeneity, and immune suppression.
• Detailed the complex interplay between CAR-T cells and the TME.
• Cataloged various engineering approaches to enhance CAR-T cell function within the TME.

Conclusions:

• Mitigating inhibitory TME factors is crucial for successful CAR-T cell therapy in solid tumors.
• A deeper understanding of CAR-T cell-TME interactions is essential for developing more effective treatments.
• Engineering CAR-T cells to overcome TME challenges holds significant promise for future solid tumor treatment strategies.